This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Implied Volatility Surging for BioMarin Stock Options
by Zacks Equity Research
Investors need to pay close attention to BMRN stock based on the movements in the options market lately.
BMRNNegative Net Change
biotechnology biotechs medical
Incyte Gears Up to Report Q1 Earnings: Here's What You Should Know
by Zacks Equity Research
INCY is likely to beat Q1 earnings estimates, primarily driven by increased U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.
NVSPositive Net Change INCYPositive Net Change CTMXNegative Net Change ARGXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
5 Stocks With Recent Price Strength Amid Tariff-Led Volatility
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are HRTG, MRX, KINS, ANIP, HCI.
MRXPositive Net Change HCIPositive Net Change ANIPPositive Net Change HRTGPositive Net Change KINSNegative Net Change
biotechnology finance insurance
Regeneron to Report Q1 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports first-quarter results on April 29.
REGNPositive Net Change AZNPositive Net Change GILDNegative Net Change VRTXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?
by Ahan Chakraborty
Let's look at five big pharma companies, GILD, BMY, MRK, ABBV and SNY slated to release their first-quarter 2025 results this week.
SNYPositive Net Change BMYPositive Net Change MRKPositive Net Change GILDNegative Net Change ABBVPositive Net Change
biotechnology biotechs medical pharmaceuticals
Novartis to Report Q1 Earnings: Will Key Drugs Maintain Momentum?
by Zacks Equity Research
NVS' first-quarter performance has likely benefited from strong growth in Kisqali, Kesimpta, Pluvicto, Leqvio, Scemblix and Fabhalta.
AZNPositive Net Change NVSPositive Net Change GILDNegative Net Change VRTXNegative Net Change
biotechnology medical pharmaceuticals
LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study
by Zacks Equity Research
Eli Lilly's stock surges as its investigational oral GLP-1 pill, orforglipron, achieves the primary and key secondary goals in the first late-stage study for adults with T2D.
NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy, Hold, or Sell BMY Stock Ahead of Q1 Earnings?
by Ekta Bagri
Bristol Myers is looking to turn its business around, banking on the strong uptake of new drugs. However, the 2025 outlook is not bright and we recommend investors to wait and watch for now.
BMYPositive Net Change PFENo Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Should You Buy, Hold, or Sell GILD Stock Ahead of Q1 Earnings?
by Ekta Bagri
Gilead Sciences' leading HIV business might face a slowdown in 2025, even though a potential approval of lenacapavir would be a significant boost. We recommend investors to wait and watch for now.
GSKPositive Net Change MRKPositive Net Change GILDNegative Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Top Beauty and Cosmetics Stocks to Boost Your Portfolio
by Ansuiya Mohta
Leading beauty and cosmetics stocks like EL, COTY and ULTA are thriving on innovation, technological advancements and sustainability.
ELNegative Net Change ULTANegative Net Change NUSNegative Net Change COTYNegative Net Change ELFNegative Net Change
artificial-intelligence biotechnology consumer-staples e-commerce
Newmont Corporation (NEM) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
NEMNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
GSK's Pentavalent Meningococcal Jab Recommended for Use by ACIP
by Zacks Equity Research
The U.S. CDC's Advisory Committee recommends the use of GSK's pentavalent Penmenvy vaccine as part of the adolescent meningococcal vaccination schedule.
GSKPositive Net Change DVAXNegative Net Change BAYRYNegative Net Change ADMANegative Net Change
biotechnology biotechs medical pharmaceuticals vaccines
Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News
by Ekta Bagri
BMY and VERV are in the spotlight this week following the failure of a late-stage study and positive cholesterol study data, respectively.
BIIBNegative Net Change IRWDNegative Net Change BMYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now?
by Ekta Bagri
At current levels, we believe GILD scores above BMY, buoyed by solid fundamentals, potential approval of lenacapavir for HIV prevention, and recent positive estimate revisions.
BMYPositive Net Change MRKPositive Net Change GILDNegative Net Change
biotechnology biotechs cancer cell-therapy medical pharmaceuticals
MURA Soars as it Explores Strategic Options Post Cancer Study Failures
by Zacks Equity Research
Mural Oncology stock skyrockets after it begins exploring strategic alternatives to maximize shareholder value after the failure of two cancer studies for nemvaleukin alfa.
DVAXNegative Net Change BAYRYNegative Net Change ADMANegative Net Change MURANegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up
by Zacks Equity Research
Precision BioSciences stock soars 24% as the FDA grants the Fast Track designation to its PBGENE-HBV gene therapy for potentially curing chronic hepatitis B.
DVAXNegative Net Change BAYRYNegative Net Change ADMANegative Net Change DTILNo Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study
by Zacks Equity Research
Verve Therapeutics stock rises on demonstrating superior LDL-C lowering ability in a phase Ib study of VERVE-102 in patients with HeFH and/or CAD.
LLYPositive Net Change BAYRYNegative Net Change ADMANegative Net Change
biotechnology biotechs gene-editing gene-therapy medical pharmaceuticals
NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback
by Ahan Chakraborty
Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.
PFENo Net Change NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
BMY Down on Heart Drug Camzyos Failure in Late-Stage Study
by Zacks Equity Research
Bristol Myers phase III study evaluating Camzyos for the treatment of adult patients with non-obstructive hypertrophic cardiomyopathy fails to meet its dual-primary endpoints.
BMYPositive Net Change FOLDPositive Net Change CYTKPositive Net Change ANIPPositive Net Change
biotechnology biotechs medical pharmaceuticals
Bayer Obtains Full FDA Approval for Oncology Drug Vitrakvi
by Zacks Equity Research
The FDA converts its accelerated approval to full approval for BAYRY's oncology drug, Vitrakvi, on positive data from confirmatory studies.
BAYRYNegative Net Change FOLDPositive Net Change ANIPPositive Net Change
biotechnology biotechs medical pharmaceuticals
NVS Plans to Invest $23B in US Manufacturing Sites Amid Tariff Threat
by Zacks Equity Research
Novartis plans to expand its current manufacturing, research and technology presence in the United States following Trump's announcement of tariffs on pharmaceutical imports.
NVSPositive Net Change BAYRYNegative Net Change ADMANegative Net Change
biotechnology medical pharmaceuticals
KROS Initiates Exploring Strategic Alternatives, Stock Gains 18.5%
by Zacks Equity Research
The stock rallies 18.5% after Keros initiates a strategic review process exploring alternatives, including a potential sale of the business.
DVAXNegative Net Change BAYRYNegative Net Change ADMANegative Net Change KROSPositive Net Change
biotechnology biotechs medical pharmaceuticals
PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose
by Zacks Equity Research
Phio Pharmaceuticals stock rallies as safety committee gives green light to advance skin cancer candidate to next dose concentration in phase I study.
DVAXNegative Net Change BAYRYNegative Net Change ADMANegative Net Change PHIONegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
ANIX Gets New Patent for Breast Cancer Vaccine Technology, Stock Up
by Zacks Equity Research
Anixa Biosciences stock jumps 13% on new patent grant for its breast cancer vaccine technology in the United States.
DVAXNegative Net Change BAYRYNegative Net Change ADMANegative Net Change ANIXNegative Net Change
biotechnology biotechs medical pharmaceuticals vaccines
Pharma Stocks Rebound as Trump Announces a 90-Day Pause on Tariffs
by Ekta Bagri
The news of a likely import tariff hurt the share price of pharma giants like Novo Nordisk (NVO), Eli Lilly (LLY) and AstraZeneca (AZN), but Trump's announcement of a pause on reciprocal tariffs offsets the losses.
AZNPositive Net Change NVONegative Net Change LLYPositive Net Change ABBVPositive Net Change
biotechnology medical pharmaceuticals